Ireland - English - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - nicotinic acid - tablet prolonged release - 750 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - nicotinic acid - tablet prolonged release - 1000 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - nicotinic acid - tablet prolonged release - 500 milligram

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia,

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia,

Canada - English - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 500mg - nicotinic acid 500mg - miscellaneous antilipemic agents

Canada - English - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 750mg - nicotinic acid 750mg - miscellaneous antilipemic agents

Canada - English - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 1000mg - nicotinic acid 1000mg - miscellaneous antilipemic agents

Canada - English - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 500mg - nicotinic acid 500mg - miscellaneous antilipemic agents

Canada - English - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 750mg - nicotinic acid 750mg - miscellaneous antilipemic agents